OKYO Pharma OKYO 深 沪
等待开盘 10-15 09:30:00 美东时间
1.415
-0.023
-1.57%
华盛通- 最 高1.45
- 今 开1.45
- 成交量 1.85万股
- 最 低 1.38
- 昨 收 1.4376
- 总市值 7425.85万
- 52周最高 3.20
- 市盈率 静 --
- 换手率 0.04%
- 52周最低 1.2648
- 委 比 -13.73%
- 总股本 5247.95万
- 历史最高 7.00
- 量 比 0.34
- 振 幅 4.87%
- 历史最低 0.8075
- 每 手 1
- 风险率 0.36%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多OKYO Pharma Announces First Patients Enrolled In Phase 3 NEPTUNE Trial Of Urcosimod For Neuropathic Corneal Pain
NEPTUNE is evaluating urcosimod as a potential first-in-class treatment for neuropathic corneal pain First patients enrolled by Dr. Melissa Toyos at Toyos Clinic in Nashville, TN LONDON and NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmace...
10-06 19:05
OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences
OKYO Pharma will present at upcoming ophthalmic conferences, including Eyecelerator on October 8, 2026, in New Orleans, and engage with experts at the American Academy of Optometry and Ophthalmology meetings. The company is committed to advancing therapies for neuropathic corneal pain (NCP) and plans to initiate a global Phase 3 clinical trial for urcosimod later this year.
09-29 11:00
OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference
OKYO Pharma Limited, a clinical-stage biopharmaceutical company developing therapies for neuropathic corneal pain (NCP) and anterior segment eye diseases, announced its participation in the Cantor Global Healthcare Conference on September 9-11, 2026. Presenters Flavio Mantelli, MD, PhD, and Gary Jacob, PhD, will discuss the company's progress during a session on September 10 at 8:35 AM ET. OKYO also plans to initiate a global Phase 3 clinical tri...
09-08 11:00
OKYO Pharma Says Chief Scientific Officer Raj Patil Purchases Of 3,363 Of Ordinary Shares On NASDAQ At $1.49 Per Share
OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that Raj Patil, PhD, Chief Scientific Officer of OKYO Pharma has increased his hol...
07-28 19:08
OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer
OKYO Pharma Limited, a clinical-stage biopharmaceutical company developing therapies for neuropathic corneal pain (NCP) and anterior segment eye diseases, announced that Raj Patil, PhD, its Chief Scientific Officer, has increased his shareholding by purchasing 3,363 ordinary shares at $1.49 per share, bringing his total holding to 20,030 shares. The company plans to initiate a global Phase 3 clinical trial this year to evaluate a single-dose regi...
07-28 11:00
OKYO Pharma chairman increases stake with share purchase
OKYO Pharma (OKYO) chairman Gabriele Cerrone, through Panetta Partners, purchased 25,000 ordinary shares at $1.40 per share. The purchase increased his total holdings to 10.85M ordinary shares. Follow...
07-21 19:54
OKYO To Initiate Global Phase 3 NEPTUNE Trial In Neuropathic Eye Pain, Enrolling 111 Patients Across US And Europe In 2026 Following Positive FDA Feedback
OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced the filing of its Annual Report on Form 20-F for the fiscal year ended March 31, ...
07-20 19:16
OKYO Pharma Announces Filing of Annual Report with Strengthened Cash Position and Accelerated Phase 3 Plans
OKYO Pharma Limited filed its 20-F annual report with the SEC, highlighting $25M raised to support the NEPTUNE Phase 3 trial for urcosimod in neuropathic corneal pain. The trial, planned for late 2026, will enroll 111 patients in the US and Europe. Urcosimod is a first-in-class chemerin peptide agonist targeting ocular inflammation and pain.
07-20 11:00
美股大行评级 | 花旗上调苹果、西部数据、希捷科技、超微电脑等目标价；高盛上调蔚来"买入"评级，目标价7美元
今日重点评级关注：HC Wainwright & Co.：维持艾吉纳斯"买入"评级，目标价从23美元升至30美元；富国银行：上调Q32 Bio评级至"超配"，目标价66美元
07-14 11:36
OKYO Pharma Announces Positive Feedback From FDA Type D Meeting, Validating Regulatory, Clinical Path Forward For Urcosimod And Supporting Advancement Into Global Phase 3 Pivotal Trial For NCP
FDA alignment on a single-dose Phase 3 study design and potential single-trial registration pathway further strengthens the Company's clinical development program for urcosimod Company unveils NEPTUNE (Neuropathic Eye Pain Treatment with Urcosimod & Nerve Evaluation), a global trial in the United St...
07-08 19:03
